Peregrine Pharmaceuticals Inc

Find Ratings Reports
PPHM : NASDAQ : Health Care
$4.58 -0.08 | -1.7%
Today's Range: 4.3866 - 4.87
Avg. Daily Volume: 226900.0
07/25/17 - 1:58 PM ET

Financial Analysis


PEREGRINE PHARMACEUTICLS INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. PEREGRINE PHARMACEUTICLS INC has weak liquidity. Currently, the Quick Ratio is 0.87 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has increased by 7.00% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)17.918.78
EBITDA ($mil)-4.69-11.3
EBIT ($mil)-5.3-11.92
Net Income ($mil)-5.27-11.88


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)46.861.41
Total Assets ($mil)118.11109.04
Total Debt ($mil)0.00.0
Equity ($mil)53.5850.07


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin37.6251.51
EBITDA Margin-26.2-60.16
Operating Margin-29.62-63.44
Sales Turnover0.490.41
Return on Assets-23.84-51.03
Return on Equity-61.21-120.09
Debt Q4 FY16 Q4 FY15
Current Ratio1.421.42
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)44.0133.85
Div / share0.00.0
EPS-0.14-0.35
Book value / share1.221.48
Institutional Own % n/a n/a
Avg Daily Volume961822.03779662.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 4.29 indicates a premium versus the S&P 500 average of 3.07 and a significant discount versus the industry average of 11.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, PEREGRINE PHARMACEUTICLS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
PPHM NM Peers 44.01   PPHM NM Peers 43.69

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

PPHM's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

PPHM's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
PPHM NA Peers 27.93   PPHM NA Peers 0.55

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

PPHM's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
PPHM 4.29 Peers 11.44   PPHM 53.58 Peers -7.96

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

PPHM is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

PPHM is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
PPHM 3.99 Peers 190.63   PPHM 28.96 Peers 434.91

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

PPHM is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

PPHM significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades